Royal Philips beat expectations in Q3 2025, raised full-year outlook, and reaffirmed 2045 net-zero goal.

Royal Philips reported stronger-than-expected third-quarter results for 2025, with comparable sales up 3% to €4.3 billion and adjusted EBITA margin expanding to 12.3%, driven by favorable product mix, cost savings, and strong North American performance. The company raised its full-year outlook, now expecting the upper end of its adjusted EBITA margin range. Revenue growth was fueled by all segments, with Personal Health leading at 10.9% growth. Philips reaffirmed its full-year sales forecast of 1%-3% and confirmed its net-zero target by 2045 has been validated. The company also highlighted AI-powered medical innovations, new product launches, and ongoing productivity initiatives, while downplaying the impact of U.S. tariffs and addressing ongoing legal matters related to a past recall.